Transcatheter Aortic Valve Replacement in Aortic Regurgitation.

Abstract BACKGROUND Evidence about safety and efficacy of transcatheter aortic valve replacement (TAVR) remains limited for patients with aortic regurgitation (AR). METHODS From the Safety & Efficacy of the J-Valve Ausper System in Patients with Severe Aortic Stenosis and/or Aortic Regurgitation Registry, the clinical outcomes of patients with AR from West China Hospital were analyzed. RESULTS A total of 134 patients with a mean Society of Thoracic Surgeons risk score of 9.8% underwent TAVR with J-Valve. Thereinto, 5 (3.7%) were converted to surgical aortic valve replacement. The cumulative all-cause mortality was 3.0% at 30 days and 3.7% at 6 months. One (0.7%) major bleeding, 1 (0.7%) major vascular complication, 8 (6.0%) acute kidney diseases, 12 (9.0%) III atrial-ventricular block and 1 (0.7%) paravalvular leakage ≥ moderate occurred. The device success rate was 96.3%. Mean ejection fraction improved from 52.1% to 57.1% (p CONCLUSIONS TAVR with J-Valve proved acceptable early and mid-term clinical outcomes for patients with AR. To the best of our knowledge, this is the largest single-center study that evaluates the safety and efficacy of TAVR in treating AR.